The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand in I&I.

Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.